<DOC>
	<DOCNO>NCT00674206</DOCNO>
	<brief_summary>The purpose study investigate combination gemcitabine oxaliplatin effective triple negative breast cancer .</brief_summary>
	<brief_title>A Phase II Trial Gemcitabine Oxaliplatin Triple Negative Metastatic Breast Cancer</brief_title>
	<detailed_description>In study , participant receive gemcitabine oxaliplatin , drug use long time . Gemcitabine treatment effective therapy currently available patient type stage breast cancer . Frequently , cancer therapy , combination drug prove effective treatment drug use alone . The combination gemcitabine oxaliplatin test patient triple negative breast cancer . It hop addition oxaliplatin may cause tumor stop grow possible tumor may shrink . This assessment basd measuring change size tumor .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically cytologically confirm ER , PR , Her2neu ( Triple Negative ) metastatic breast cancer Patients must measurable disease accord RECIST criterion . Patients bone metastasis may include decrease performance status narcotic analgesic requirement . Patients must either receive taxane adjuvant set receive taxane firstline treatment metastatic breast cancer Age &gt; 18 year ECOG Performance Score 0 , 1 , 2 ( Appendix A ) Adequate bone marrow evidence : Absolute neutrophil count &gt; 1,500/L Platelet count &gt; 100,000/microL Adequate renal function evidence serum creatinine &lt; 1.5 mg/dL Adequate hepatic function evidence : Serum total bilirubin &lt; 1.5 mg/dL Alkaline phosphatase &lt; 3X ULN reference lab &lt; 5X ULN ( Upper limit normal ) patient know hepatic metastasis SGOT/SGPT &lt; 3X ULN ( Upper limit normal ) reference lab ( &lt; 5X ULN patient know hepatic metastasis Patients must recover acute late effect prior surgery , radiotherapy antineoplastic therapy Patients legal representative must able read , understand provide inform consent participate trial . Patients childbearing potential agree use effective form contraception study 90 day follow last dose study medication ( effective form contraception oral contraceptive double barrier method ) Patients active infection fever &gt; 101.30 F within 3 day first schedule day protocol treatment Patients active CNS metastasis . Patients stable CNS disease , undergone radiotherapy least 4 week prior plan first protocol treatment stable dose corticosteroid 3 week eligible trial History prior malignancy within past 5 year except curatively treat basal cell carcinoma skin , cervical intraepithelial neoplasia , localized prostate cancer current PSA &lt; 1.0 mg/dL 2 successive evaluation least 3 month apart , recent evaluation within 4 week entry Patients know hypersensitivity component oxaliplatin gemcitabine . Patients receive gemcitabine platinbased chemotherapy past . Patients receive chemotherapy within 28 day first schedule day protocol treatment . Patients receive radiotherapy 25 % bone marrow ; patient receive radiotherapy within 4 week entry Patients receive concurrent investigational therapy receive investigational therapy within 28 day first schedule day protocol treatment ( investigational therapy define treatment currently regulatory authority approve indication ) Peripheral neuropathy Grade 2 Patients pregnant lactate Any medical condition , include mental illness substance abuse , deem Investigator likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result . History allogeneic transplant Known HIV Hepatitis B C ( active , previously treat )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Metastatic breast cancer</keyword>
</DOC>